Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Altimmune, Inc.

NASDAQ: ALT · Life Sciences · 8 alerts · CIK 1326190

Share price
$1.56Close, Nov 16
Market cap
$304M
Shares outstanding
194.59MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Altimmune, Inc. filings on SEC EDGAR ↗

4:28 PM ET Form 4
Insider Buying

Altimmune CFO Gregory L. Weaver Buys $16.2K of Stock

Gregory L. Weaver, CFO, bought 10,000 shares of Altimmune, Inc. at $1.62 a share, worth $16.2K in total on Nov 13, 2026. Shares held after the trade: 73,005 (+15.9%).

Value
$16.2K
Shares
10,000
Price
$1.62
Role
CFO
Holding change
+15.9%
Trade date
Nov 13, 2026
4:27 PM ET Form 4
Insider Buying

Altimmune Director Wayne Pisano Buys $16.4K of Stock

Wayne Pisano, Director, bought 10,000 shares of Altimmune, Inc. at $1.64 a share, worth $16.4K in total on Nov 13, 2026. Shares held after the trade: 58,800 (+20.5%).

Value
$16.4K
Shares
10,000
Price
$1.64
Role
Director
Holding change
+20.5%
Trade date
Nov 13, 2026
4:27 PM ET Form 4
Insider Buying

Altimmune President and CEO Jerome Benedict Durso Buys $49.7K of Stock

Jerome Benedict Durso, President and CEO, bought 30,700 shares of Altimmune, Inc. at $1.62 a share, worth $49.7K in total on Nov 13, 2026. Shares held after the trade: 93,200 (+49.1%).

Value
$49.7K
Shares
30,700
Price
$1.62
Role
President and CEO
Holding change
+49.1%
Trade date
Nov 13, 2026
4:34 PM ET 10-Q
Financial Results

Altimmune Q3 2026 Results: Net Loss of $31.6M, Loss Widens

Altimmune, Inc. reported a net loss of $77.0 million for the nine months ended September 30, 2026, compared to $60.7 million in the prior year, driven by increased research and development expenses. The company significantly strengthened its balance sheet through public and direct offerings, ending the period with $495.6 million in total assets, including $265.1 million in cash and investments.

Key figure
Net loss $31.6M
7:34 AM ET 8-K
Financial Results

Altimmune Financial Results

Altimmune reported third quarter 2026 financial results and provided a business update on its pemvidutide clinical programs. The company ended the quarter with $480 million in cash and is progressing its Phase 3 PERFORMA trial in MASH and preparing for an End-of-Phase 2 meeting with the FDA for its AUD program in December 2026.

“We continue to make significant progress across all our clinical development programs, as we execute our strategy of building a liver franchise around pemvidutide. Our global PERFORMA Phase 3 trial in MASH is ramping up, and we are very encouraged by the progress to date and the enthusiasm we see from the MASH community.”

Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune

“In AUD, we look forward to engaging with the FDA in an End-of-Phase 2 meeting where we will leverage our strong RECLAIM data to discuss a Phase 3 registrational program. Following the recent AASLD meeting, our conviction in pemvidutide’s potential is stronger than ever, as we focus on delivering meaningful benefit to patients with serious liver diseases.”

Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.